News

This is a developing news story. Please check back soon for updates. Alcon will acquire LumiThera, including its ...
(Reuters) -European shares ended higher on Tuesday, boosted by healthcare and energy shares while investors assessed the latest phase of U.S. President Donald Trump's tariff rollouts, which included a ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...
introducing competition to Novo Nordisk and Eli Lilly in China's obesity drug market. Elon Musk criticizes the Senate tax and spending bill, warning it will harm American jobs and undermine ...
Wall Street achieved record highs as healthcare stocks saw notable movements.
Novo Nordisk (NVO) said it expanded patient access to Wegovy through a new collaboration with WeightWatchers, beginning July 1. WeightWatchers will work with CenterWell Pharmacy as the dispensing ...
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests ...